JUNO cancer treatment toxicity, good summary of th
Post# of 72440
https://smithonstocks.com/juno-therapeutics-c...uno-27-87/
Quote:
The side effect profile of the CAR-T cells is as troubling as efficacy is promising. We have seen severe, life threatening side effects related to cytokine release syndrome and neurological toxicities that have led to deaths. I have been astounded at how little attention has been paid to this drawback by analysts and investors and have just shaken my head in disbelief at the multi-billion valuations given to Juno and Kite. The side effect risk element is brought home by the announcement yesterday by Juno of three deaths in a trial they are conducting........
The patient deaths strongly emphasize that while this is an extremely potent therapy that it is accompanied by very serious life threatening side effects. Drugs are ultimately judged on the balance of efficacy versus side effects. I think that there has been over-emphasis on efficacy while turning a blind eye to these dangerous side effects. The side effect risk may not be adequately incorporated in the stock prices even after the hit they took today.
I trust this will provide a response to anyone who also posts elsewhere, where they have been claiming that Kevetrin, with its excellent safety profile, would be "unnecessary."